Publications by authors named "Z EVEN PAZ"

Aims: To examine whether biologic disease-modifying anti-rheumatic drugs (bDMARDs) are associated with increased risk of malignancy among Israeli patients with rheumatoid arthritis (RA).

Methods: We identified RA patients meeting specified inclusion and exclusion criteria from the Leumit healthcare services database between the years 2000 and 2017. Data were collected regarding bDMARD and conventional DMARD consumption, types of malignancies, and their temporal relation to RA diagnosis.

View Article and Find Full Text PDF

Introduction: Active metabolite of vitamin D has neuro-immunomodulatory and neuroprotective properties. However, there is still a debate about the potential association between low serum levels of hydroxy-vitamin D and increased risk for dementia.

Objectives: To determine an association between hypovitaminosis D and dementia for different 25-hydroxyvitamin-D (25(OH)D) serum level cutoffs.

View Article and Find Full Text PDF
Article Synopsis
  • Primary hyperoxaluria type 1 (PH1) is a genetic disorder that impacts oxalate metabolism, leading to kidney failure, with liver transplantation being the primary treatment option.
  • A study analyzed the long-term kidney outcomes of pre-emptive liver transplantation (PLT) compared to conservative treatment for PH1 patients from 1997 to 2017.
  • Results showed that patients who received PLT maintained better kidney function over time, with none reaching stage 5 chronic kidney disease, while the majority of those not receiving PLT eventually did.
View Article and Find Full Text PDF

Background: Septic arthritis (SA) is associated with significant morbidity and mortality. Delayed or inadequate treatment may result in joint destruction, osteomyelitis and sepsis. Like other types of infection, the causative agents of SA may have changed over time.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the lack of head-to-head trials comparing different biologic disease-modifying antirheumatic drugs (bDMARDs) for treating rheumatoid arthritis (RA), making the choice largely dependent on rheumatologists' preferences.
  • Researchers conducted a retrospective analysis of 4,268 RA patients from 2000-2017, finding that only 19.2% received bDMARDs, with infliximab showing the longest average drug survival of 47.1 months, while golimumab had the shortest at 14.9 months.
  • Key factors linked to longer drug survival included being male, using concurrent conventional DMARDs, and starting bDMARD therapy in earlier calendar years.*
View Article and Find Full Text PDF